AXIN1 and cancer: Inhibition of TNKS1/2 by small molecule inhibitors (TNKSi) has emerged as a promising new cancer therapeutic approach as it leads to stabilization of AXIN1/2 and a concomitant reduction in β-catenin protein levels and transcriptional activity in vitro and in vivo [8, 12–15].